Skip to main content
Fig. 2 | Trials

Fig. 2

From: Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial

Fig. 2

Planned visiting and examination schedule *will be used as baseline values. Vital signs include: blood pressure, heart rate, weight at every visit; height only at screening visit. Motor Function Measurement (MFM) scale, 6-min Walking Distance Test (6MWD), quantitative motor tests (QMT), and screening will be used as baseline values. Full blood count: erythrocytes, reticulocytes, leucocytes, platelets, haemoglobin, haematocrit. GOT, GPT, creatinine, electrolytes (Na+, K+, Ca2+), urea, creatine kinase (CK), glycosylated haemoglobin (HbA1c), cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, calculated glomerular filtration rate (GFR). Oxidised DNA (8-hydroxy-2’-deoxyguanosine: 8OHDG), carbonylated proteins (4-Hydroxynonenal (4-HNE)), mitochondrial proteins (citratsynthase, cytochrome C oxidase subunit 1, succinate dehydrogenase subunit A), nitrotyrosine, cGMP. Woman of child-bearing potential. SIPP – Self-reported Impairments in Persons with late effects of Polio, IBM-FRS – Inclusion Body Myositis Functional Rating Scale, WHOQOL-BREF – The WHO Quality of Life – BREF Questionnaire

Back to article page